Skip to contentO
Opus Genetics, Inc.
O
IRDOpus Genetics, Inc. Q2 2026 · 10-Q
Revenue$755.00K$755.00K−73.8% vs Q2 2025 Net Income-$8.10M-$8.10MN/M vs Q2 2025 EPS Diluted-$0.14-$0.14N/M vs Q2 2025 Operating Income-$16,480,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Opus Genetics, Inc. · CIK 1228627 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-2182.8%−1873.8 pt vs Q2 2025
Net margin-1072.6%−815.1 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 6, 2026 · 37 d after period end